top of page
Thrombectomy Penetration Remains Low
And why point-of-care diagnostics may be the fastest way to change it Mechanical thrombectomy is no longer an emerging therapy. It is one of the clearest advances in acute stroke care over the past decade, supported by strong clinical evidence, stable reimbursement, and broadening guideline support. In clinical terms, the debate has largely been settled. For the right patients, treated quickly enough, thrombectomy changes outcomes. And yet the market remains materially underp
Apr 234 min read
What the Boston Scientific–Penumbra acquisition signals, and why it matters for Wellumio
Boston Scientific’s announced ~$14.5 billion acquisition of Penumbra marks one of the most significant medtech transactions in recent years. While often framed as a return to neurovascular intervention, the deeper signal is more consequential: time-critical acute care has become strategic infrastructure. For companies building upstream of intervention, the implications are material. From portfolio category to strategic necessity More than a decade ago, Boston Scientific exite
Jan 263 min read
Wellumio and MEYTEC Sign MoU to Pioneer Next-Generation Stroke Imaging and Telemedicine Integration
WERNEUCHEN, GERMANY & MELBOURNE, AUSTRALIA MEYTEC, a leader in telemedicine and mobile emergency care technologies, and Wellumio, an...
May 20, 20252 min read
.png)
_edited.jpg)
.png)
Keep up to date with the latest industry thinking
Thrombectomy Penetration Remains Low
And why point-of-care diagnostics may be the fastest way to change it Mechanical thrombectomy is no longer an emerging therapy. It is one of the clearest advances in acute stroke care over the past decade, supported by strong clinical evidence, stable reimbursement, and broadening guideline support. In clinical terms, the debate has largely been settled. For the right patients, treated quickly enough, thrombectomy changes outcomes. And yet the market remains materially underp
Thrombectomy Penetration Remains Low
And why point-of-care diagnostics may be the fastest way to change it Mechanical thrombectomy is no longer an emerging therapy. It is one of the clearest advances in acute stroke care over the past decade, supported by strong clinical evidence, stable reimbursement, and broadening guideline support. In clinical terms, the debate has largely been settled. For the right patients, treated quickly enough, thrombectomy changes outcomes. And yet the market remains materially underp
What the Boston Scientific–Penumbra acquisition signals, and why it matters for Wellumio
Boston Scientific’s announced ~$14.5 billion acquisition of Penumbra marks one of the most significant medtech transactions in recent years. While often framed as a return to neurovascular intervention, the deeper signal is more consequential: time-critical acute care has become strategic infrastructure. For companies building upstream of intervention, the implications are material. From portfolio category to strategic necessity More than a decade ago, Boston Scientific exite
Check back soon
Once posts are published, you’ll see them here.
Thrombectomy Penetration Remains Low
And why point-of-care diagnostics may be the fastest way to change it Mechanical thrombectomy is no longer an emerging therapy. It is one of the clearest advances in acute stroke care over the past decade, supported by strong clinical evidence, stable reimbursement, and broadening guideline support. In clinical terms, the debate has largely been settled. For the right patients, treated quickly enough, thrombectomy changes outcomes. And yet the market remains materially underp
Let's talk
If you can help towards our mission of reshaping the future of imaging, we'd like to hear from you.
We believe that improving access to MR technology is key to solving long-standing health delivery challenges.
bottom of page